Spyre Therapeutics (SYRE) EBT (2015 - 2026)
Spyre Therapeutics (SYRE) posted EBT of -$69.0 million for Q1 2026, down 10.36% on a QoQ basis from -$62.5 million in Q4 2025, and down 54.07% year-over-year from -$150.2 million in Q1 2025.
Spyre Therapeutics (SYRE) EBT (2015 - 2026) Analysis & Trends
Spyre Therapeutics' EBT history runs 12 years deep, the most recent figure standing at -$69.0 million for Q1 2026.
- Quarterly EBT fell 54.07% year-over-year to -$69.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$179.4 million (up 14.12% YoY) and the FY2025 annual result came in at -$155.2 million, up 25.36% from the prior year.
- EBT was -$69.0 million for Q1 2026 at Spyre Therapeutics, down from -$62.5 million in the prior quarter.
- Across five years, EBT topped out at -$11.2 million in Q3 2025 and bottomed at -$217.1 million in Q2 2023.
- A 5-year average of -$50.3 million and a median of -$40.1 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT tumbled 872.82% — and 2025, when it soared 83.8%.
- Spyre Therapeutics' EBT stood at -$18.8 million in 2022, then tumbled by 236.35% to -$63.2 million in 2023, then advanced by 10.9% to -$56.3 million in 2024, then dropped by 11.08% to -$62.5 million in 2025, then fell by 10.36% to -$69.0 million in 2026.
- Business Quant data shows SYRE's EBT at -$69.0 million in Q1 2026, -$62.5 million in Q4 2025, and -$11.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | -69.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.01 Mn |
| Dec 31, 2025 | -62.53 Mn |
| Sep 30, 2025 | -11.18 Mn |
| Jun 30, 2025 | -36.72 Mn |
| Mar 31, 2025 | -44.79 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Sep 30, 2024 | -69.01 Mn |
| Jun 30, 2024 | -38.84 Mn |
| Mar 31, 2024 | -43.83 Mn |
| Dec 31, 2023 | -63.18 Mn |
| Sep 30, 2023 | -40.10 Mn |
| Jun 30, 2023 | -217.07 Mn |
| Mar 31, 2023 | -18.46 Mn |
| Dec 31, 2022 | -18.78 Mn |
| Sep 30, 2022 | -18.44 Mn |
| Jun 30, 2022 | -22.31 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.42 Mn |
| Sep 30, 2021 | -20.28 Mn |
| Jun 30, 2021 | -6.74 Mn |